2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transfusion, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4541 Patient- and physician-reported barriers affecting receipt of chimeric antigen receptor T-cell therapy in multiple myeloma after referral

Sikander Ailawadhi, MD, Nicole Niehoff, PhD, MPH2, Natalie Boytsov, PhD3, Teresa Palumbo, DMSc, PA-C4, Kelly Brock, PharmD5, Molly Purser, PhD6, Abigail Herbst7, Bridget Gaglio8, Daniel Bretton9, Martin Parkinson10, Natasha Edwin, MD11
1 Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, United States
2 GSK, Durham, NC, United States
3 GSK, Upper Providence, PA, United States
4 GSK, New York, NY, United States
5 GSK, Durham, NC, United States
6 GSK, Upper Providence, PA, United States
7 PPD Evidera Solutions, a part of Thermo Fisher Scientific, Waltham, MA, United States
8 PPD Evidera Solutions, a part of Thermo Fisher Scientific, Waltham, MA, United States
9 PPD Evidera Solutions, a part of Thermo Fisher Scientific, London, United Kingdom
10 PPD Evidera Solutions, a part of Thermo Fisher Scientific, London, United Kingdom
11 Providence Cancer Center Oncology and Hematology Care Clinic, Portland, OR, United States

Introduction: Multiple myeloma (MM) treatment has been transformed by novel B-cell maturation antigen (BCMA)-targeted therapy options including chimeric antigen receptor T-cell (CAR-T) treatment, bispecific antibodies, and an antibody-drug conjugate. Unmet needs remain for patients with MM, as despite known survival benefits, access to anti-BCMA therapies is limited. Two CAR-T therapies that target BCMA, idecabtagene vicleucel and ciltacabtagene autoleucel, have been associated with manufacturing and logistical challenges, and specialized care is required for administration. In line with these challenges, a real-world study of patients with MM who received leukapheresis identified that >50% of the patients were observed not to receive CAR-T (Ailawadhi S, et al. J Clin Oncol. 2026;44[16 suppl]:7530). This study reports the reasons for not receiving, or delays in receiving, CAR-T infusion after intention to treat (ITT) from the perspective of patients and physicians in the US.

Methods: A non-interventional, one-time, cross-sectional, web-based survey of physicians and patients from US academic or community centers was performed. Physician eligibility criteria included working in the US, working in an academic or community clinical setting, and experience in treating, prescribing/referring, or managing CAR-T treatment, as well as the ability to complete an English web-based survey. Eligible patients had self-reported MM and must have been prescribed CAR-T in the past year and either received, did not respond to, or had been referred to but not yet received treatment. Patients were able to provide electronic consent and complete a web-based survey in English/Spanish. Data collection was between March–April 2026. Data were analyzed descriptively.

Results: Of the 45 patients in total across both the community and academic setting who were referred and eligible for CAR-T, 32 had completed CAR-T treatment and 13 had been referred for treatment but did not, or had not received CAR-T infusion at the time of the survey; patients in academic and community centers were combined for reporting due to the sample size. Among the 13 patients who did not receive CAR-T infusion, the most common responses when patients were asked why they had not received CAR-T was that they were still considering whether CAR-T was right for them (54%), treatment was not available locally or would require relocation (46%), and concern about supportive care needed after infusion (46%). Only 1 patient (8%), reported disease progression as the reason they did not receive CAR-T therapy.

In total, 46 physicians (n=30 academic, n=16 community) provided data on their CAR-T treatment prescribing experience. In academic/community centers, physicians reported disease progression while awaiting CAR-T infusion as the primary reason (reported as frequently or very frequently occurring) for patients’ failure to receive treatment after ITT (63%/88%); patient-related factors (e.g. age, comorbidities, treatment hesitation) were also reported as a factor in non-receipt of CAR-T therapy (37%/56%), as well as unacceptable wait times (40%/44%). The physician-reported median (range) percentage of patients that died during the period between confirmed ITT and CAR-T infusion was 8% (0–80) and 5% (0–40) in academic and community centers, respectively. The median (range) estimated number of days between ITT and decision not to pursue CAR-T or death was 30 (12–120) days in community centers and 23 (3–90) days in academic centers.

Conclusions: This study reinforces the unmet need for BCMA-targeting therapies that are easily accessible, have convenient administration, and do not require delays prior to treatment. Novel insights from patients with MM into the barriers to CAR-T therapy after referral for treatment included patient hesitation and logistical concerns such as local access to treatment and supportive care requirements. Physicians identified patients having disease progression, patient-related factors including age, comorbidities and hesitation, as well as unacceptable wait times, as barriers to receipt of CAR-T therapy. These results highlight the unmet need for BCMA-targeting modalities that provide transformational survival benefits for patients with MM while increasing accessibility for all patients.

Sikander Ailawadhi, MD: BMS - Research Funding; Xencor - Research Funding; Cellectar - Research Funding; Janssen - Research Funding; Ascentage Pharma Group Inc. - Research Funding; Amgen - Research Funding; Pharmacyclics - Research Funding; AbbVie - Research Funding; GSK - Research Funding; GSK - Consultancy (Includes expert testimony); Cellectar - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony)